Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

156.22
-0.3500-0.22%
Post-market: 156.220.00000.00%17:00 EDT
Volume:890.85K
Turnover:139.70M
Market Cap:15.93B
PE:22.90
High:159.67
Open:157.20
Low:156.12
Close:156.57
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.00
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.31
PE(LYR):33.45

Loading ...

Neurocrine price target raised to $155 from $140 at Truist

TIPRANKS
·
May 07

Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says

MT Newswires Live
·
May 06

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine (NBIX)

TIPRANKS
·
May 06

Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades

Stock Track
·
May 06

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Fresenius Medical Care (FMS) and American Well (AMWL)

TIPRANKS
·
May 06

Neurocrine Is Maintained at Outperform by Wedbush

Dow Jones
·
May 06

Neurocrine publishes expert guidance on glucocorticoid tapering after starting Crenessity in CAH

Reuters
·
May 06

Morgan Stanley Raises Price Target on Neurocrine Biosciences to $191 From $185, Keeps Equalweight Rating

MT Newswires Live
·
May 06

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction After Initiating Crenessity® (Crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

THOMSON REUTERS
·
May 06

Neurocrine Biosciences : Oppenheimer Raises Target Price to $230 From $220

THOMSON REUTERS
·
May 06

J.P. Morgan Keeps Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
May 06

Neurocrine (NBIX) Gets a Buy from Piper Sandler

TIPRANKS
·
May 06

Neurocrine (NBIX) Receives a Buy from Guggenheim

TIPRANKS
·
May 06

Neurocrine Biosciences Inc : Morgan Stanley Raises Target Price to $191.00 From $185.00

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Citigroup Raises Target Price to $246 From $242

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Inc : Piper Sandler Raises Target Price to $207 From $190

THOMSON REUTERS
·
May 06

Neurocrine Biosciences Delivers Record Quarter, Eyes 2027

TIPRANKS
·
May 06

Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand

TIPRANKS
·
May 06

Neurocrine Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating

TIPRANKS
·
May 06